Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly (ADP-ribose) dependent pathway in the early response to DNA-damaging agents by Haince, J. F. et al.
Ataxia Telangiectasia Mutated (ATM) Signaling Network Is
Modulated by a Novel Poly(ADP-ribose)-dependent Pathway
in the Early Response to DNA-damaging Agents*□S
Received for publication,August 31, 2006, and in revised form, April 10, 2007 Published, JBC Papers in Press, April 11, 2007, DOI 10.1074/jbc.M608406200
Jean-Franc¸ois Haince‡1, Sergei Kozlov§, Valina L. Dawson¶2, Ted M. Dawson¶2,3, Michael J. Hendzel,
Martin F. Lavin§, and Guy G. Poirier‡4
From the ‡Health and Environment Unit, Laval University Hospital Research Center, CHUQ, Faculty of Medicine, Laval University,
Quebec, Quebec G1V 4G2, Canada, the §Queensland Institute for Medical Research, PO Royal Brisbane Hospital, Brisbane,
Queensland 4029, Australia, the ¶Institute for Cell Engineering and the Departments of Neurology and Neuroscience,
The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and the Department of Oncology,
Faculty of Medicine, University of Alberta and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada
Poly(ADP-ribosyl)ation is a post-translational modification
that is instantly stimulated by DNA strand breaks creating a
unique signal for the modulation of protein functions in DNA
repair and cell cycle checkpoint pathways. Here we report that
lack of poly(ADP-ribose) synthesis leads to a compromised
response toDNAdamage.Deficiency in poly(ADP-ribosyl)ation
metabolism induces profound cellular sensitivity to DNA-dam-
aging agents, particularly in cells deficient for the protein kinase
ataxia telangiectasia mutated (ATM). At the biochemical level,
we examined the significance of poly(ADP-ribose) synthesis on
the regulation of early DNA damage-induced signaling cascade
initiated by ATM. Using potent PARP inhibitors and PARP-1
knock-out cells, we demonstrate a functional interplay between
ATM and poly(ADP-ribose) that is important for the phospho-
rylation of p53, SMC1, andH2AX. For the first time, we demon-
strate a functional and physical interaction between the major
DSB signaling kinase, ATM and poly(ADP-ribosyl)ation by
PARP-1, a key enzymeof chromatin remodeling.This study sug-
gests that poly(ADP-ribose) might serve as a DNA damage sen-
sory molecule that is critical for early DNA damage signaling.
Double-strand breaks (DSB)5 are potentially the most cyto-
toxic form of DNA damage in human cells because they lead to
genomic rearrangements, cancer predisposition, and perhaps
cell death if unrepaired or repaired incorrectly (1). Conse-
quently, the DNA damage response involves parallel modula-
tion of redundant signaling pathways leading to lesion detec-
tion, processing, and repair. Ataxia telangiectasia mutated
(ATM) is aDNAdamage-responding kinase that is rapidly acti-
vated after the induction of DSB (2). Within minutes of DNA
damage induction, ATM is recruited and activated in the vicin-
ity of DSBs, where it induces the phosphorylation of a number
of proteins required for DNA damage response and repair,
including proteins of MRN (Mre11/Rad50/NBS1) complex,
p53, SMC1 and histone variant H2AX (3). However, the
detailedmechanisms of howATM is activated and regulates its
downstream effectors are not fully understood. AlthoughATM
activation is mainly associated with DSB formation as part of
the damage detection mechanism following ionizing radiation
(IR), several studies indicate that the signaling kinase ATM is
also activated in response to the environmental carcinogen
N-methyl-N-nitro-N-nitrosoguanidine (MNNG) (4–6).
Poly(ADP-ribose) polymerases (PARPs) are also constitutive
factors of the DNA damage surveillance network, acting
through a DNA break sensor function (7). Several observations
indicate that poly(ADP-ribosyl)ation also plays an early role in
DSB signaling and repair pathways (8–11). PARP-1 and
PARP-2 are highly activated upon binding toDNAstrand inter-
ruptions and synthesize, within seconds, large amounts of the
negatively charged polymer of ADP-ribose (PAR) on several
nuclear proteins including themselves, histones, topoisomerase
I, and DNA-dependent protein kinase (DNA-PK) (12). The
immediate activation of PARP-1 byDNAbreaks and the result-
ing PAR build-up, which appears minutes after DNA damage
induction, are among the earliest cell responses to DNA dam-
age (13–15). After initial recruitment of PARP-1 to DNA
lesions, hyperpoly(ADP-ribosyl)ated PARP-1 dissociates from
the DNA template (16), leading to relaxation of chromatin
structure (17), which may facilitate the recruitment of repair
proteins to damaged sites via direct interactions with PAR (18).
Furthermore, multiple reports show that PARP inhibitors
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increase the cytotoxicity of DNA-damaging agents and IR (19–
21). This ismanifested by a delay in the progression through the
S phase and accumulation of cells in G2/M (22, 23). Although
viable, both PARP-1 and PARP-2 knock-out mice display an
acute sensitivity to IR and alkylating agents (24, 25). PARP-1/
PARP-2 double knock-out mice die at early stages of embryo-
genesis, demonstrating the crucial functions of poly(ADP-ribo-
syl)ation in DNA damage signaling and the existence of
functional redundancy between these twoPARPs (25). Interest-
ingly, PARP-1/ATMdoublemutantmice are defective for both
repair and signaling of DNA damage, leading to embryonic
lethality because of their dramatic sensitivity to DNA damage
(26, 27).
Recently, the notion that PAR mediates key events in cell
cycle regulation such as mitotic spindle control through PAR
binding interaction (28–30) stimulated our interest on the pos-
sible role of PAR-binding proteins in early DNA damage
response and specifically the interplay between the signaling
kinase ATM and PAR molecules. A number of proteins
involved in DNA damage signaling contain modular domains
that mediate specific protein-protein interactions. Conse-
quently, a PAR-binding domain has been found in a number of
proteins involved in DNA damage response pathways such as
p53, p21, XRCC1, Ku70, topoisomerase I, and DNA ligase III
(31–34). However, despite major advances primarily by bio-
chemical and genetic studies, the precise role of poly(ADP-ri-
bosyl)ation in the immediateDNAdamage signaling remains to
be elucidated. The finding that ATM is activated, at least in
vitro, by PARmolecules (35) raises the issue as to whether PAR
influences the phosphorylation cascade initiated by the ATM
protein kinase.
In this study, we determined how PAR synthesis modulated
the early DNA damage signaling response. We show that
impaired PAR synthesis in cells treated with the PARP inhibi-
tors is associated with delayed phosphorylation of p53, H2AX,
and SMC1 after DNA damage caused by treatment with both
MNNG and IR. The decreased phosphorylation and stabiliza-
tion of p53 and delayed phosphorylation of SMC1 and histone
H2AX were also confirmed in mouse embryonic fibroblasts
(MEFs) derived fromPARP-1/mice. In addition, we demon-
strate that PAR interacts physically with ATM, that this inter-
action is mediated by PAR-binding domains and that it has
functional consequences.
MATERIALS ANDMETHODS
Cell Lines—The human lung adenocarcinoma cells (A549)
(ATCC CCL-185) were maintained in Ham’s F12K medium
with 2 mM glutamine containing 15% fetal bovine serum, peni-
cillin (100 units/ml), and streptomycin (100 g/ml). SV40-
transformed normal skin fibroblasts (GM00637), and A-T
fibroblasts (GM09607) as well as mouse embryonic fibroblasts
derived from PARP-1/ (F20) and PARP-1/ (A1) mice (36)
were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, glutamine (2 mM), peni-
cillin (100 units/ml), and streptomycin (100 g/ml). Alterna-
tively, the EBV-immortalized normal lymphoblastoid cells
(C3ABR) and A-T lymphoblastoid cells (GM03189) were used
andmaintained in RMPI 1640medium supplementedwith 15%
fetal bovine serum, glutamine (2mM), penicillin (100 units/ml),
and streptomycin (100 g/ml).
Immunoprecipitation, Western Blotting, and Antibodies—
We exposed control and A-T cells to genotoxic agents (MNNG
and IR) and collected whole cell extracts at the indicated time
points as described (37).We performed precipitation of endog-
enous PARP-1 with an anti-PARP-1monoclonal antibody (F1–
23). Cells were resuspended in 25 mM NaPO4 buffer pH 8, 150
mMNaCl, 1mMEDTA, 0.2%Nonidet P-40, 1mMdithiothreitol,
1 mM phenylmethylsulfonyl fluoride, and protease inhibitors
CompleteTM (Roche Applied Science) and kept on ice for 20
min. NaPO4 andNaCl concentration were then adjusted to 175
mM (150 l/ml) and 0.3 M (30 l/ml), respectively, and homog-
enized using a Dounce homogenizer with 30 strokes with the
tight-fitting pestle. A suspension of magnetic protein G beads
(Invitrogen) was washed twice with binding buffer (175 mM
NaPO4, pH 8.0 containing 150 mM NaCl, 1 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and prote-
ase inhibitors) prior to immunoprecipitation. Cleared lysate
was diluted to 1:2 (v/v) with binding buffer without NaCl,
mixed with the antibody-coated beads, and incubated with
rotation at 4 °C for 90–120 min. The beads were washed with
the binding buffer. The beads containing the immunoprecipi-
tated samples were collected, resuspended in 250 l of SDS
loading buffer and boiled 5 min at 100 °C. Whole cell extracts
(10 g) or immunoprecipitates were analyzed by SDS-PAGE
and electrotransferred onto nitrocellulose membranes.
Immunoblots were probed with antibodies directed against
PAR (96–10 antisera), PARP-1 (clone C2–10), p53 protein,
p53 phospho-S15, SMC1 phospho-S957, SMC1 (Cell Signal-
ing), H2AX phospho-S139 (Upstate), and -actin (Calbio-
chem). Immunoblots were developed using the Super Signal
West Dura Extended Duration (Pierce) to allow quantitative
analysis.
Purification of GST-ATM Fragments and in Vitro Pull-down
Assays—For in vitro PAR binding characterization, we pre-
pared a series of GST-ATM constructs as described (38). For
the GST pull-down, glutathione-Sepharose beads (80 l) were
washed with lysis buffer and then resuspended in 400l of lysis
buffer containing either purified GST-tagged ATM domains (1
g) or GST protein alone. For each condition, PARP-1 (1 g),
32P-modified PARP-1 (100nM), PARG (1unit), or PAR (100nM)
were added to the reaction mixture. After a 2-h incubation at
4 °C with constant mixing, the beads were washed extensively
in lysis buffer containing 500 mM NaCl. The beads were col-
lected by centrifugation, resuspended in 250 l of SDS loading
buffer and boiled 5 min at 100 °C. After separation by SDS-
PAGE, bound material was detected by autoradiography,
immunoblotting with anti-PARP-1 (clone C2–10) or Coomas-
sie Blue staining.
Nitrocellulose PAR Binding Assay—Synthetic peptides or
purified proteins were loaded onto a nitrocellulose membrane
(0.1 m pore size) using a dot blot manifold system. Mem-
branes were incubated with 32P-labeled automodified PARP-1
or 32P-labeled purified PAR prepared as described (39), washed
extensively, and subjected to autoradiography.
BioPorter-mediated Delivery of Peptides into Cells—Wild-
type and mutant ATMN-terminal PAR-binding peptides were
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delivered into cells using the BioPorter reagent (Sigma) (40, 41).
Purified peptides were diluted to the desired concentration in
PBS. The diluted peptide solution (2.5g of total) was added to
the dried BioPorter reagent and allowed to sit at room temper-
ature for 5 min followed by gentle mixing. The suspensions
were mixed with 250 l of serum-free medium and were then
added to cells (60–80% confluency) cultured in 6-well cell
culture plates for 3–4 h at 37 °C. Cultures were subsequently
used for experiments.
Cytotoxicity Studies—Cells were suspended in RPMI 1640
medium and plated out at 2  105 cells/ml in 24-well cell cul-
ture plates. Cells were exposed for 1 h to a range of concentra-
tions of the PARP inhibitor PJ-34 (Axxora) or a range ofMNNG
concentrations in growth medium. After treatment, fresh
media with or without PJ-34 was added, and plates were incu-
bated for 4–5 days at 37 °C in a 10% CO2 incubator until
untreated control cells reached2 106 cells/ml. Cell viability
(triplicate wells for each drug concentration) was determined
by adding 0.1ml of 0.4%Trypan blue to a 0.5-ml cell suspension
(42). Viable cells were counted, and viabilitieswere expressed as
the number of cells in drug-treated wells relative to cells in
control wells (% of control).
Immunofluorescence and Microscopy Analysis—A549 or
GM00637 cellswere fixed at the indicated timepoints following
treatment with DNA-damaging agents (MNNG or IR). PAR
synthesis was detected with the rabbit anti-PAR 96–10 anti-
body. Nuclear foci of DNA damage were visualized using anti-
H2AX pS139 monoclonal antibody (Upstate). Cells were
observed using a Zeiss microscope (Axioplan IIM) equipped
with a CoolSnapHQ cooled CCD camera. Themeasurement of
fluorescence intensity and colocalization was performed using
MetaMorph 6.0 (Universal Imaging) software. Composite fig-
ures of collected images were assembled in Adobe Photoshop.
Confocal Microscopy and Quantification of -H2AX Foci—
To detect MNNG-induced -H2AX foci, PARP-1/ and
PARP-1/ MEF grown on coverslips were fixed at various
time points afterMNNGexposure and stainedwith anti-H2AX
pS139 monoclonal antibody. Cells labeled as described above
were placed on a Nikon inverted confocal laser-scanning
microscope and images were captured using the LaserSharp
software. The number of -H2AX foci per cell were manually
counted in three separate fields (at least 50 cells/fields). Cells
were classified into four different categories according to the
number of -H2AX foci per cell (0–5, 5–15, 15–30, or more
than 30 foci per cell).
Cell Cycle Analysis—Cell cycle distribution after PJ-34 and
MNNG treatments was determined by flow cytometry analysis
using propidium iodine staining for DNA content. Cell death
was characterized by the number of cells with fragmentedDNA
(sub-G1 population).
RESULTS
Loss of PAR Synthesis Sensitizes Normal Cells to DNA-dam-
aging Agents—Genetic disorders that cause deficiency in DNA
damage signaling proteins are characterized by an increased
sensitivity to a variety of DNA-damaging agents. Cells derived
from patients with Ataxia-Telangiectasia (A-T) illustrate per-
fectly this paradigm showing a defective response toDNAdam-
age (43). Similarly, it has been demonstrated that disruption of
PAR synthesis causes an increase in sensitivity to DNA-damag-
ing agents (21), suggesting that deficiency in PARmetabolism is
linked to a defect inDNAdamage signaling. Thus, to determine
whether the effects of PARP inhibition impacts on the ATM
signaling network, we compared the sensitivity to DNA alkylat-
ing agents in normal ATM-proficient lymphoblasts and in A-T
patient cells. As shown in Fig. 1A, normal cells exposed for one
hour to bothMNNG and PARP inhibitors exhibit survival rates
similar to A-T cells treated with MNNG alone, suggesting that
the absence of PAR synthesis decreases the ability of normal
cells to respond adequately toDNAdamage to an extent similar
to that observed in A-T cells.
FIGURE 1. Normal and A-T cells are hypersensitive to MNNG-induced DNA damage in the absence of poly(ADP-ribosyl)ation. A, viability of normal
lymphoblastoid cells (C3ABR) and lymphoblastoid cells derived from an A-T patient (GM03189) treated with increasing concentrations of MNNG alone or in
combination with 5 M PJ-34 was evaluated as described under “Materials and Methods.” B, cell survival was also determined after exposure to increasing
concentrations of PJ-34 to establish its relative cytotoxicity. Data are the mean S.E. from three independent experiments.
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We next evaluated whether PJ-34 exhibits inhibitor-specific
toxicity in the absence of treatment with exogenous cytotoxic
drugs using survival as readout (Fig. 1B). We observed a rela-
tively low toxicity in normal ATM-proficient cells when low
doses of PJ-34 were added to growth medium (Fig. 1B). How-
ever, A-T cells are acutely sensitive to treatment with the same
low doses of PJ-34 (Fig. 1B). This finding is consistent with
previous reports showing that deficiency in DNA damage sig-
naling proteins induces sensitivity to PARP inhibition (10, 26).
We also established that the hypersensitivity of A-T cells to the
suppression of PARP-1 function is due to the activation of apo-
ptosis (supplemental Fig. S1). This is illustrated by the
increased sub-G1 population (supplemental Fig. S1B) and the
appearance of the specific PARP-1 cleavage product (supple-
mental Fig. S1C). Together, these results clearly show that dis-
ruption of PARP function by chemical inhibition in normal
cells leads to the suppression of an important signaling event of
the DNA damage response that is comparable to the cell sur-
vival defect observed in cells lacking ATM.
MNNG Induces ATM-dependent Substrate Phosphorylation
That Is Altered in the Absence of PAR Synthesis—The DNA
damage-responsive kinase ATM is best known for its activation
following IR (2). Besides, ATM has also been proven to be the
main kinase responsible for the phosphorylation of p53 on ser-
ine 15 duringMNNG-induced DNA damage (4). In addition, it
was shown that NBS1, SMC1, and p53 were phosphorylated in
an ATM-dependent manner at high doses of MNNG-induced
DNA strand breaks, while ATR responds to the formation of
DNA adducts and stalled replication induced by UV radiation
(4–6). We have analyzed this specific phosphorylation of p53
using a large panel of normal ATM-proficient and A-T cell
lines. All ATM-proficient cells show induction of p53 phospho-
rylation 1 h after MNNG treatment (Fig. 2A). In contrast, neg-
ligible signal was detected in both A-T cell lines exposed to the
same treatment (Fig. 2A). Taken together, these findings con-
firm that high MNNG doses activate the ATM kinase, which
allow the direct and rapid phosphorylation of p53 on serine 15
(4, 6). Therefore, we usedMNNG to activate bothATMprotein
kinase and PAR formation to establish the relationship between
ATM and PARP-1.
We hypothesized that PARmolecules might influence ATM
function, either by promoting its kinase activity or by providing
access to its downstream substrates. Recent studies have dem-
onstrated that ATM kinase activity is significantly enhanced by
PAR (35). Because poly(ADP-ribosyl)ation occurs with kinetics
similar to that of ATM activation during initial steps of the
DNA damage signaling (27), it is therefore conceivable that
PAR could trigger ATM phosphorylation of a subset of its tar-
gets within the first hour after DNA breaks formation. To
understand themechanismof PARP-1 activation in response to
MNNG, we first determined the time-course of PARP activa-
tion in normal and A-T cells as well as in PARP-inhibited cells
exposed to 50 M MNNG (Fig. 2B). Exposure of both normal
and A-T cells to MNNG results in an immediate synthesis of
PAR that peaks at 30min post-treatment, and rapidly decreases
after 1 h, demonstrating how fast the PAR-dependent response
can be (Fig. 2,B andC). However, in cells exposed to a 5Mdose
of PJ-34, we observed a striking inhibition (98.5%) of PAR syn-
thesis following MNNG exposure (Fig. 2, B and C). Having
observed that DNA damage-dependent PAR synthesis follows
rapid kinetics in both normal and A-T cells, we next examined
the ATM-dependent response within the same time frame fol-
lowing treatment with both MNNG and PJ-34. We performed
biochemical analysis on the well-established ATM substrates
p53, SMC1, and H2AX using phosphospecific antibodies.
Importantly, cells treatedwith bothMNNGandPJ-34 present a
5-fold decrease of p53 phosphorylation at 30 min and 1 h post-
treatment (Fig. 2B-C). Pretreatment of the cells with PJ-34 sig-
nificantly reduced the MNNG-induced phosphorylation of
SMC1 on serine 957 throughout the treatment (Fig. 2,B andC).
Next we used an ATM-deficient cell line to determine whether
the phosphorylation cascade induced by MNNG is dependent
of the protein kinase ATM. Although these cells demonstrate
normal level of PAR synthesis followingMNNG exposure, they
exhibit a defective phosphorylation of ATM-dependent sub-
strates p53, SMC1 and H2AX (Fig. 2, B and C). Besides, no
phosphorylation of p53 and SMC1 was observed in the ATM-
deficient cells when PAR synthesis peaks (1 h). This indicates
that PAR could not signal directly to othermembers of the PI3K
kinase family such asATRandDNA-PK. Importantly, we found
that treatment of A-T lymphoblasts withMNNG greatly atten-
uated the phosphorylation of p53 and SMC1 in initial time
points, which demonstrated that the protein kinase ATM is
responsible phosphorylation of these effectors following
MNNG exposure. Together these results suggest that the
absence of PAR modulates the ATM-dependent phosphoryla-
tion of numerous downstream effectors including p53 and
SMC1 immediately afterMNNGexposure. Similar effects were
also observed with another PARP inhibitor, DPQ (supplemen-
tal Fig. S2). In these cells, over 90% of the PAR synthesis was
inhibited 1 h after treatment (data not shown) and theMNNG-
induced phosphorylation of p53 is about 60% of that measured
when PAR is fully synthesized (supplemental Fig. S2). These
results indicate that the reduced phosphorylation of p53 is due
to the absence of PAR rather than a PJ-34 specific effect.
The ability of -H2AX to form nuclear foci upon DNA dam-
age has long been recognized as a sensitive marker of DSB for-
mation (44, 45). Consequently, we noticed a 26% reduction of
FIGURE 2.Disruption of PAR synthesis affects theMNNG-inducedDNAdamage response. A, panel of ATM-proficient (A549, GM00637, C3ABR) cells along
with ATM-deficient (GM09607, GM03189) cells were treated with MNNG (50 M) for 1 h and harvested. The phosphorylation state of p53 on serine 15 was
analyzedbyWesternblottingusingaphosphospecific antisera. The immunoblotswere thenprobed for total p53andactin.B, A549 cellswerepretreatedornot
for 1 hwith PJ-34 (5M) prior to addition of MNNG (50M) and comparedwith ATM-deficient cells (GM03189) treatedwith the same dose of MNNG. Total cell
extracts were prepared at indicated time points following MNNG exposure and immunoblotted with antibodies directed against PAR (pAb 96-10), phospho-
SMC1 (serine 957), SMC1, phospho-p53 (serine 15), p53, -H2AX, and actin (loading control). C, quantification of PAR synthesis, p53 phosphorylation on serine
15, -H2AX and SMC1 phosphorylation on serine 957 were performed directly on immunoblots shown in B. D, A549 cells were immunostained with anti-PAR
polyclonal antibody 96-10 and anti-H2AX monoclonal antibody at the indicated time points following 50 M MNNG treatments. Bottom panels show
co-localization of -H2AX foci with sites of PAR synthesis. Data are representative of at least three independent experiments.
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H2AX phosphorylation at serine 139 within the first hour of
treatment with both MNNG and PJ-34 (Fig. 2C). Therefore, to
determine whether PAR synthesis occurred predominantly at
sites of -H2AX foci formation, we treated A549 cells with the
alkylating agent MNNG and examined the colocalization
between early -H2AX foci formation and PARnuclear synthe-
sis by indirect immunofluorescence. MNNG treatment caused
a marked increase in phosphorylation of H2AX in a time-
course similar to that of PAR synthesis (Fig. 2D). As seen in Fig.
2D, PAR colocalizes with sites of -H2AX foci formation. Col-
lectively, these results strongly support the hypothesis that PAR
is an early DNA damage signaling molecule that connects with
ATM-signaling cascade.
PARP-1-deficient Cells Have an
Impaired DNA Damage Response—
It has been suggested earlier that
enzymatic activity of PARP-1 is
required for p53 stabilization
(46–48). Therefore, we examined
whether MEFs deficient in PARP-1
were also defective in early MNNG-
induced DNA damage response as
determined by p53 phosphorylation
and stabilization. Phosphorylation
of p53 is generally associated with
its stabilization and nuclear accu-
mulation (49). Accordingly, we
show that PARP-1-deficient MEFs
exhibit a severe deficiency in p53
phosphorylation (on serine 18 in
mouse p53) and accumulation (Fig.
3A) consistent with the delayed
phosphorylation of p53 observed in
cells treated with a chemical inhibi-
tor following MNNG treatment
(Fig. 2B). Interestingly, the rapid
ATM-dependent phosphorylation
of SMC1 at serine 957 was also seri-
ously impaired in PARP-1-deficient
cells exposed to MNNG (Fig. 3A),
confirming the defects observed
with cells treated with PJ-34.
We have shown that sites of
intense poly(ADP-ribosyl)ation co-
localize with -H2AX in distinct
nuclear foci generated by MNNG
(Fig. 2D). Thus, to further define the
requirement of PARP-1 activity in
the early signaling of DNA damage
formation, we investigated the
kinetics of -H2AX foci formation
in PARP-1-deficient MEFs follow-
ing exposure to MNNG. Without
MNNG treatment, -H2AX foci
were barely detected in PARP-1/
MEFs, but a small number of
-H2AX foci could be observed in
PARP-1/MEFs (data not shown).
Although -H2AX foci formationwas induced in both cell lines
30 min after MNNG treatment (Fig. 3B), the rate of -H2AX
foci formation was markedly slower in PARP-1/ cells, con-
firming the involvement of PARP-1 activity in signaling the
presence of damaged DNA. Quantitative image analysis of
-H2AX-positive cells showed that both cell lines have almost
equal number of -H2AX foci, 4 h after MNNG exposure (Fig.
3C), suggesting that DNA damage-induced -H2AX foci for-
mation is delayed but not completely abrogated in the absence
of PAR formation. However, 8 h after MNNG treatment, cells
lacking PARP-1 showed a marked increase in the number of
cells positive for -H2AX foci, with about 65% of the cells con-
tainingmore than 15-H2AX foci per cell comparedwith 8% in
FIGURE 3. PARP-1-deficient cells have impaired p53 stabilization and defective -H2AX foci formation.
A, total extract from wild type (PARP-1/) and knock-out (PARP-1/) MEFs were immunoblotted against
PARP-1, phospho-SMC1 (serine 957), SMC1, phospho-p53 (serine 18 in mice), and p53 at the indicated time
points following 50MMNNG treatments. PARP-1 statuswas assessed byWestern blot using PARP-1 antibody
and equal gel loading was verified using an anti-actin antibody. Quantification of MNNG-induced -H2AX foci
formation in PARP-1/ and PARP-1/MEF. Cells were treatedwith 50MMNNG, fixed and immunoassayed
with anti-phospho-H2AX (serine 139)monoclonal antibody. Confocal microscopy images of -H2AX foci were
counted at (B) 30min, (C) 4 h, and (D) 8 h after MNNG treatment. For the determination of -H2AX foci per cell,
multiple fields were examined to count at least 150 cells for each time point.
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cells proficient in PARP-1 and subjected to the same treatment
(Fig. 3D). These data suggest that enzymatic activity of PARP-1
is required to resolve DNAbreaks induced by genotoxic agents.
Poly(ADP-ribosyl)ation Modifies the Effectiveness of the
ATM-signaling Response Induced by Ionizing Radiation—The
influence of poly(ADP-ribosyl)ation on DNA repair following
IR has been studied in the past using potent PARP inhibitors
(47, 48). In particular, it has been observed in various human
cancer cell lines that inhibition of PAR synthesis enhance the
cell-killing effect of -irradiation (19, 21). Although the molec-
ular events associated with this increased cytotoxicity are
unknown, several recent observations imply a role for poly-
(ADP-ribosyl)ation in the ATM/ATR signaling pathways. To
test whether PAR synthesis is involved in this pathway, ATM-
mediated phosphorylation of p53, SMC1, and H2AX was ana-
lyzed in -irradiated (10Gy) cells treatedwith or without PJ-34.
We first determined the time course of PAR formation follow-
ing IR in these conditions (Fig. 4A). PAR synthesis peaked rap-
idly and declined within 15 min after IR for both normal and
A-T cells, demonstrating the transient nature of poly(ADP-ri-
bosyl)ation (Fig. 4,A andB). In contrast, negligible PAR synthe-
sis could be detected in cells pretreated for 1 h with PJ-34 (Fig.
4, A and B). As expected, IR treatment also rapidly stimulated
phosphorylation of the main ATM targets p53, SMC1, and
H2AX (Fig. 4A). In contrast, cells treated with PJ-34 only show
a limited phosphorylation of ATMeffectors at early time points
after IR (Fig. 4A). Although the effect was not as marked as that
seen in MNNG-treated cells, we observed a significant delay in
p53 serine 15 phosphorylation between 5 and 30 min after
exposure to IR and PJ-34 (Fig. 4, A and B). As previously
reported, the phosphorylation of p53 is almost exclusively
dependent on ATM kinase activity at these early time point
after irradiation (50). As a result, A-T cells exposed to IR do not
exhibit phosphorylation of the ATM main targets p53, SMC1,
andH2AX. Interestingly, treatment of cells with PJ-34 decrease
the ATM-dependent phosphorylation of SMC1 to a level com-
parable with that observed in A-T cells (Fig. 4, A and B), sug-
gesting a dependence between PAR and ATM in the initial
response to IR. Moreover, following concomitant exposure to
IR and PJ-34, the phosphorylation ofH2AX at serine 139 is only
one third of thatmeasured 15min after cells have been exposed
to IR only (Fig. 4, A and B). To determine whether the ATM-
dependent phosphorylation of H2AX in response to IR-in-
duced DSBs is mediated in association with PAR synthesis, we
directly evaluated the presence of PAR signal at DSB-flanking
regions by indirect immunofluorescence using anti--H2AX
phosphospecific antibody. Again, PAR synthesis clearly spreads
throughout DSB regions marked by -H2AX (Fig. 4C). These
results thus suggest that the functional interplay between PAR
and ATM prevails in DNA damage response induced by differ-
ent types of damaging agents.
Poly(ADP-ribose) and ATM Physically Interact—The mech-
anism underlying the interplay between the early PAR-depend-
ent signaling pathway and the activation of the DNA damage-
responsive kinase ATM might be mediated by a direct
interaction between ATM and PAR. Thus, to verify whether
ATM directly binds PAR molecules, we used twelve overlap-
ping GST-tagged ATM domains (Fig. 5E) (38) spanning the
entire ATM protein in a quantitative in vitro PAR-binding
assay. The GST-tagged N-terminal amino acid region (GST-
ATM1; 1–246) and PI3K domain of ATM (GST-ATM10;
2427–2840) specifically bound PAR while the GST-tag alone
did not (Fig. 5, A–C). As a positive control, core histones
exposed to 100 nM of either modified PARP-1 or free PAR
showed strong binding affinities (Fig. 5, B and C, first lane). To
test whether PAR directly mediates the interaction between
PARP-1 and ATM, we performed specific pull-down experi-
ments using the GST-ATM fusion proteins that exhibited PAR
binding activity. Both domains specifically interact with either
poly(ADP-ribosyl)ated PARP-1 (Fig. 5D, lanes 8 and 13) or
purified PAR (Fig. 5D, lanes 10 and 15) but fail to bind PARP-1
alone or modified PARP-1 after hydrolysis of PAR by poly-
(ADP-ribose) glycohydrolase (PARG) (Fig. 5D, lanes 7, 9, 12,
and 14, respectively). The presence of PARP-1 in GST precipi-
tates was verified byWestern blot using a monoclonal PARP-1
antibody (Fig. 5D). The fact that PARP-1 could not be detected
inGSTpull downwith purified PARP-1 (Fig. 5D, lanes 7 and 12)
or modified PARP-1 after PAR was hydrolyzed by PARG (Fig.
5D, lanes 9 and 14) clearly demonstrated that these ATM
regions do not directly bind to PARP-1 unless it is poly(ADP-
ribosyl)ated. These results support the idea that these two
regions of the ATM protein might comprise a functional
domain that mediates direct interaction with PAR.
ATM Has Two Putative PAR-binding Domains—Based on a
previous report on PAR-binding proteins, we have determined
key amino acids that dictate affinity and specificity for PAR
interaction and identified two putative PAR-binding domains
within theseATMregions (Fig. 5E). Typically, the PAR-binding
domain comprises a core of 20 amino acids characterized by the
presence of hydrophobic and determinant repeated basic resi-
dues flanked by noncontiguous basic residues that provide
additional contact to PARmolecules (34, 51). The first putative
PAR-binding domain extended from amino acids 99–120 of
ATM (Fig. 5E) and is located in the chromatin-association
domain (52). The second domain lies in the C-terminal region
within amino acids 2738–2760, and partly overlaps the PI3K
domain of ATM (Fig. 5E). Comparison of the putative ATM
PAR-binding sites from human, mouse, and pig sequences
shows that the N-terminal binding site (99–120) is highly con-
served with the consensus sequence (Fig. 5E). As shown in a
recent report, the N-terminal protein interaction domain of
ATM resides specifically within amino acids 81–106 (53) and is
essential for the interaction with and phosphorylation of p53
(38). Thus, the fact that ATM interacts with PAR molecules
through its N-terminal domain, provides a functional link for
cross-talk between PAR synthesis and ATM activation.
To demonstrate the affinity of these ATM PAR-binding
domains to specifically bind PAR, small mimetic peptides cor-
responding to the putative PAR-binding domains (99–120 and
2738–2760) were designed (Fig. 6A). Previous studies have
used synthetic peptides in a similar PAR-binding assay and
demonstrated that several DNA damage proteins can specifi-
cally bind PAR (34, 54). The PAR binding assay showed that
ATM 99–120 and ATM 2738–2760 peptides do indeed bind
PAR in vitro (Fig. 6B). It has been suggested that PAR binding
requires the presence of basic residues in the amino acid
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sequence (34, 51, 55). Hence, to determine whether any basic
amino acid residues are required for ATM-PAR interaction, we
took advantage of the binding affinity of the ATM peptide
99–120 in which the basic amino acids of the binding site were
replaced by alanines.We observed that substitution of the basic
repeat (ATM S3) or the C-terminal basic residues (ATM S4)
FIGURE4. Irradiation-inducedDNAdamage response is delayed in theabsenceofPAR.A, ATM-proficient lymphoblastoid cellswerepre-treatedwith 5M
PJ-34 for 1 h prior to DNA damage induction with -irradiation (10 Gy) and compared with ATM-proficient and -deficient cells exposed only to IR. Total cell
extracts where then immunoblotted with phosphospecific antibodies directed against known downstream effectors of ATM. B, densitometric quantification
of PAR synthesis, p53 phosphorylation on serine 15, and -H2AX were performed directly on immunoblots shown in A. C, GM00637 cells were irradiated with
5 Gy and fixedwithin 5min before immunostainingwith anti-PAR and -H2AX antibodies. Data are representative of at least three independent experiments.
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considerably reduce the ability of substituted peptides to inter-
act with PAR (Fig. 6, B and C). To explore the possible mech-
anism by which PAR affected the ATM function, we used a
lipid-mediated formulation to achieved intracellular deliv-
ery of peptides derived from the N-terminal PAR-binding
domain of ATM protein kinase (ATM 99–120) in intact cells
(40, 41). After intracellular delivery of the PAR-binding pep-
tide ATM 99–120, phosphorylated ATM was easily detect-
able by immunostaining. Although these cells exhibited nor-
mal levels of autophosphorylated ATM, they are defective
for foci formation (Fig. 6D). Notably, this effect has not been
observed for the recruitment of other DSB sensors at DNA
damage sites including 53BP1 (Fig. 6E). Most importantly,
the administration of PAR-binding peptides, where impor-
tant basic residues were substituted by alanine (ATM S4),
failed to disrupt ATM pS1981 foci formation under the same
condition (Fig. 6D). To test whether the ATM 99–120 pep-
tide has an influence on ATM mediated downstream pro-
cesses, the phosphorylation of p53 on serine 15 was studied.
After treatment with MNNG (50 M, 1 h), cells treated with
ATM 99–120 peptide exhibited a noticeable dose-depend-
ent reduction of p53 phosphorylation, whereas levels of p53
phosphorylation in cells treated with ATM S4 peptide was
largely unchanged (Fig. 6F). The immunofluoresence results
combined with Western blotting data clearly suggest that
ATM is activated followingMNNG treatment and that intra-
cellular delivery of the ATM 99–120 peptide preclude the
accumulation of phosphorylated ATM at DNA damage sites.
The quantitative decrease of ATM-dependent p53 phospho-
rylation observed by immunoblot after treatment with the
ATM 99–120 peptide is likely related to this mislocalization
of autophosphorylated ATM. Thus, specific binding to PAR
does not seem to be required for the initial activation of
ATM, but rather appear to play an important role in recruit-
ing activated ATM to the sites of DNA breaks, where it can
then phosphorylate substrates, including p53, SMC1, and
H2AX. These observations suggest that the abnormal DNA
damage response seen in cells with impaired PAR synthesis
result from a defective ATM migration to sites of DNA
breaks. Our results subsequently imply that optimal activa-
FIGURE 5. Biochemical analysis of the interaction between ATM and PAR. A, SYPRO Ruby Red protein blot staining of purified GST-ATM fusion proteins
schematized in E. Autoradiography of PAR-binding GST-ATM fusion proteins incubated with 100 nM of either (B) 32P-labeled automodified PARP-1 or (C)
purified 32P-labeled PAR. D, mapping of the region of ATM that interacts with PAR by pull-down assays with purified PARP-1, modified PARP-1 and PAR was
performed as described under “Materials and Methods.” Autoradiograms show the presence of PAR in the pull-down fraction. Detection of PARP-1 in the
pull-down fraction was achieved byWestern blotting. Coomassie Blue gel staining reveals the amount of precipitated GST-tagged protein. The lanes 1, 6, and
11 represent purified GST protein input. E, schematic representation of the series of GST-ATM constructs (38). Shown below is the domain architecture of
full-length ATM protein. The two putative PAR-binding sites are indicated in black. Alignment of human, mouse, and pig ATM sequences with the consensus
PAR-binding domain is also shown. SwissProt accession numbers are provided. Conserved basic amino residues are indicated in bold against a light gray
background.
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tion of the ATM-mediated DNA damage response requires
PAR synthesis.
Finally, we tested the possibility that PARP-1 might interact
with the ATM signaling network in vivo. Intracellular interac-
tion between PARP-1 and ATM has been identified by co-im-
munoprecipitation (IP) of endogenous PARP-1 protein fol-
lowed byWestern blotting detection of ATM (Fig. 6G).We also
immunoprecipitated endogenous PARP-1 following MNNG
treatment and determined the level of poly(ADP-ribosyl)ation
using anti-PAR antibody (Fig. 6G). Of note, Mre11, a key com-
ponent of MRN complex, was also found in the same IP and is
present in a relatively higher amount in IPs from MNNG-
treated cells (Fig. 6G). Collectively, these results demonstrate
that ATM and PAR can physically interact together which is
likely to be achieved by a specific PAR-binding domain.
DISCUSSION
DNA damage response pathways are essential for the main-
tenance of genomic integrity and mammalian cells have devel-
oped an intricate signaling network that allows the detection of
FIGURE 6. Identification of functional PAR-binding sites within ATM protein kinase. A, synthetic mimetic peptides corresponding to the putative PAR-
binding motif of ATM were generated with or without alanine substitutions. Conserved basic residues are indicated in bold against a light gray background.
B, indicated peptides were blotted onto nitrocellulosemembrane and analyzed for PAR binding affinity. p21 peptide was used as a positive control (34) and a
short unrelatedpeptide sequencewas thenegative control. Theupper panel shows a SYPRORubyRed stainingof blottedpeptides and confirms equal loading.
The middle panel shows that ATM PAR-binding motif peptide binds to 100 nM equivalent of PAR amount covalently attached to PARP-1. The lower panel
presents the nitrocellulose PAR binding assay in the presence of purified 100 nM 32P-labeled PAR. C, PAR binding capacity of ATM99–120 peptide and
alanine-substituted peptides (ATMS1 to ATM S4) was quantified using Cerenkov counting of 32P-labeled free PAR bound to nitrocellulose. D, defective foci
formation of DSB repair molecules in cells treated with PAR-binding mimetic peptides. Mimetic peptides (2.5 g) were introduce in human adenocarcinoma
cells A549 using the BioPorter delivery system 4 h before treatment with 50 M MNNG. Following MNNG treatment, the DNA damage-induced activation of
ATM was monitored by serine 1981 autophosphorylation at 30 min and correlates with PAR synthesis detected using anti-PAR antibody. E, foci formation of
DSB-sensing factor 53BP1 in cells treated with PAR-binding mimetic peptides. F, cells were treated with increasing amount of PAR-binding mimetic peptides
andphosphorylationof theATMdownstreamtargetp53wasmonitoredbyWesternblottingusingp53 serine15phosphospecific antibody30minafterMNNG
treatement. Actin was used as a loading control. G, in vivo IP analysis of PARP-1 interaction with ATM protein kinase using C3ABR total cell extracts treated or
not with 50 M MNNG for 1 h.
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DNA lesions by sensors, leading to transduction of signals by
effector proteins, resulting in the activation of checkpoint path-
ways that transiently arrest cell cycle progression to allow
repair. A long standing question in the PARP field has been
whether poly(ADP-ribosyl)ation is a true modulator of this
early DNA damage signaling pathway. Evidence suggests that
disruption of poly(ADP-ribosyl)ation metabolism by chemical
inhibition or genetic disruption of PARP-1 significantly
decreases cell survival, specifically in association with genetic
disorders where homologous recombination (HR) is compro-
mised (8–10). Similarly, cells with impaired ATM function are
characterized by hypersensitivity to DSB-inducing agents and
are also defective for cell cycle checkpoint activation (43). In
this work, we confirmed that reducing PAR synthesis by chem-
ical inhibitionmarkedly increased the sensitivity of normal cells
to DNA-damaging agents (Fig. 1) and affected the activation of
cell cycle checkpoint (supplemental Fig. S1). Given that failure
in DNA damage-induced poly(ADP-ribosyl)ation causes
defects similar to those associated with ATM deficiency, we
hypothesized that the early PAR-dependent signaling response
connects with the signaling pathways controlled by ATM.
Therefore, using A-T cells, we observed that the PARP inhibi-
tor PJ-34 significantly increased cell death with or without
DNA damage (Fig. 1 and supplemental Fig. S1). This has been
previously revealed in PARP-1/ATM double knock-out cells
(26) and more recently in PARP-1-deficient cells treated with
ATM inhibitors (10, 56). Importantly, in the range of treatment
doses used in this study, PJ-34 alone did not display such toxic-
ity in normal cells (Fig. 1B). Together, these results support the
idea that PAR synthesis is involved in a functional interplay
with the ATM signaling network.
Two groups have reported that PARP inhibitors used alone
for long periods of time activate ATM, presumably through
persistence of endogenous single strand breaks that have the
potential to be converted to DSB during replication (10, 56). In
contrast, in this studywe investigated the effects of PARP inhib-
itors on the early signaling events that take place when ATM is
activated by exogenous DNA lesions created by either MNNG
or IR. Although not exclusive to ATM, several lines of evidence
indicate that the phosphorylation of p53, SMC1, and H2AX is
primarily achieved by the upstream kinase ATM in response to
DNAdamage induced by both IR andMNNG treatment (2, 50).
Our results suggest that the rapid and transient PAR formation
creates a unique signal that directly or indirectly results in acti-
vation of the ATM signaling pathway. Previous work has pro-
posed that ATM is not activated directly by binding to DNA
damage sites but rather by a signal generated by a structural
change of chromatin (2, 50). Thus, PAR molecules attached to
PARP-1 might act as a sensor and initiate a DNA damage
response through modulation of the ATM signaling pathway.
Accordingly, the PAR-binding domain identified here appears
to have a notable function for recruiting activated ATM at sites
of DNA breaks. Consequently, we demonstrate that in the
absence of PAR synthesis, ATM-dependent phosphorylation of
p53, SMC1, and H2AX is significantly reduced in cells treated
with both MNNG and IR (Figs. 2 and 4). Notably, although the
PARP-inhibited cells show a clear delay in phosphorylation of
ATM substrates after MNNG or IR treatment, this effect is less
prominent than the defect observed in a cell line deficient in
ATM (Figs. 2 and 4). We could not exclude that ATR might be
responsible for the phosphorylation of p53 and SMC1 at later
time points (1 h) in both PARP-inhibited and ATM-deficient
cells. However, it is unlikely that ATR alone could mediate the
early PAR-dependent response reported here, because no PAR-
binding domain has been found within the ATR amino acid
sequence. We clearly show that following either MNNG or IR
treatments, PAR accumulation is rapid and effectively colocal-
izes with -H2AX (Figs. 2D and 4C), which is known to accu-
mulate instantly after DNA damage in a manner that is closely
related to numbers of DSB (44). Our results are consistent with
recent studies showing that PARP-1 predominantly localizes to
DSB sites induced by microbeam irradiation (57) and directly
interacts with -H2AX in response to IR (58). However, we
noticed a delayed accumulation and a longer persistence of
-H2AX foci in PARP-1/ cells in response to genotoxic
exposure (Fig. 3), presumably reflecting a defect in the DNA
damage repair pathway.
To our knowledge, we are the first group to demonstrate and
characterize a direct interaction between ATM and PAR using
both GST fusion domains of ATM and specific peptides mim-
icking ATM PAR-binding domains (Figs. 5 and 6). GST-pull
downs specifically show that ATM will bind to PARP-1 exclu-
sively when PAR is present (Fig. 5D). Moreover, using small
peptides which were expected to mimic the ATM 99–120 and
ATM 2738–2760 PAR-binding domains, we confirmed exper-
imentally that ATM does indeed bind PAR in vitro through
those sequences (Fig. 6B). In contrast, peptides carrying muta-
tions in critical basic positions of PAR-binding domain ATM
99–120 (ATM S3 and ATM S4) lost their affinity for PAR (Fig.
6,B andC). Furthermore, introduction of wild-typeATMPAR-
binding peptides (ATM 99–120) in living cells disrupted the
focus formation of phosphorylated ATM but not of other DSB
repair molecules in cells treated with MNNG, while a mutant
peptide had no effect on focus formation under the same con-
ditions (Fig. 6, D and E). Disrupting the ATM-PAR interaction
using PAR-bindingmimetic peptides prevents the proper local-
ization of ATM to DNA breaks and partially compromises the
phosphorylation of p53 in response to DNA damage (Fig. 6F).
Because it has been demonstrated that ATM is able to phos-
phorylate p53 even if it is not localized at DNA breaks (59), we
observed only a partial protection of p53 phosphorylation in
cells treated with the PAR-binding mimicking peptide ATM
99–120 (Fig. 6F). Consequently, the ability of ATM, as a medi-
ator of the DNA damage response, to recognize PAR through a
specific PAR-binding domain provides insight as to how non-
covalent PAR interactionsmight alter the functional properties
of its targets as observed following MNNG and IR treatments.
Interestingly, the PAR-binding domain located within the N
terminus of ATM (99–120) partially overlaps with the chroma-
tin-association domain (5–224), which is required for ATM
retention on chromatin and may target ATM to sites of DNA
damage (52). In addition, the ATM N-terminal PAR-binding
domain is highly conserved among species (Fig. 5E) and its
importance is highlighted by the fact that nomutation has been
reportedwithin this sequence inA-Tpatients, supporting a link
between PAR-binding and ATM functions. Overall, these
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results confirm that ATM and PAR interact together in a non-
covalent way via PAR-binding domains and support the con-
clusion that PAR is involved in the modulation of the DNA
damage response through direct interaction with signaling
proteins.
The physical association between ATM and PAR might
explain the functional consequences of PARP inhibition
observed in vivo. Incidentally, it was recently reported that
PAR activates ATM in vitro (35). In that study, Goodarzi and
Lees-Miller showed biochemically that PAR greatly stimu-
lates ATM kinase function. Although it remains unclear
whether PAR directly activates ATM in vivo, it is reasonable
to envisage a model where the presence of PAR on modified
proteins or on PARP-1 facilitates the phosphorylation of
ATM downstream targets at sites of DNA damage. This in
turn allows the induction of a proper DNA damage response
upon genotoxic exposure (Fig. 7). Disrupting this interaction
using PARP inhibitors undeniably interferes with the early
DNA damage-induced phosphorylation of ATM down-
stream targets.
It is becoming clear that PAR synthesis provides a dynamic
and transient mechanism that may be able to delicately modu-
late the activity of ATM protein kinase in cells treated with
various DNA-damaging agents. The fact that the phosphoryla-
tion of ATMsubstrates is significantly delayed in the absence of
PAR but still occurs suggests that other redundant pathways
could contribute to the recruitment of ATM to specific sites of
damaged DNA. Recent studies by Lee and Paull (60) suggest an
important role for the MRN complex as a DNA damage sensor
complex essential to the recruitment of ATMat sites surround-
ing damaged DNA. However, our results also suggest a unique
synergy between ATM and poly(ADP-ribosyl)ation in the ini-
tial steps ofDNAdamage signaling. Identification of poly(ADP-
ribosyl)ation as a critical event in this pathway constitutes an
important issue to address in future studies on genetic disor-
ders that are characterized by defectiveDNAdamage responses
and cancer predisposition.
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